Trikafta NDC 51167-106

NDC codes

FDA NDC Directory

Product NDC (as listed)51167-106Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51167-0106Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51167-106-02	51167010602	4 BLISTER PACK in 1 CARTON (51167-106-02) / 1 KIT in 1 BLISTER PACK * 14 TABLET, FILM COATED in 1 BLISTER PACK (51167-206-14) * 7 TABLET, FILM COATED in 1 BLISTER PACK (51167-306-07)Marketed from Jun 8, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Trikafta
Generic name (nonproprietary): elexacaftor, tezacaftor, and ivacaftor
Dosage form: Kit
Labeler: Vertex Pharmaceuticals Incorporated
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 212273
Marketing start: Jun 8, 2021
Listing expires: Dec 31, 2027
Identifiers: Product ID 51167-106_b63ac090-8d8b-43a0-82d1-558127f2d598SPL ID b63ac090-8d8b-43a0-82d1-558127f2d598SPL set ID f354423a-85c2-41c3-a9db-0f3aee135d8dRxCUI 1243046, 1606868, 2174388, 2257011, 2257012, 2257013, 2557214, 2557215, 2557216, 2635013, 2635020, 2635021, 2635022, 2635024, 2635025, 2635026

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N451167010602 followed by a unit qualifier and the quantity

Package 51167-0106-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 22, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients aged 2 years and older who have a clinical diagnosis of CF and who have at least one variant in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is either responsive based on clinical and/or in vitro data (see Table 6 ) or results in production of CFTR protein [see Clinical Pharmacology (12.1) ] . If the patient's genotype is unknown, an FDA-cleared CF genetic test should be used to confirm the presence of at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. TRIKAFTA is a combinati…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 212273

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 212273
Product	Strength	Form · route	Labeler	Product NDC
Trikaftaelexacaftor, tezacaftor, and ivacaftor	—	Kit	Vertex Pharmaceuticals Incorporated	51167-331